Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06266624
Other study ID # Tourniquet in HHT
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 25, 2020
Est. completion date July 30, 2024

Study information

Verified date February 2024
Source University Hospital, Essen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.


Description:

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 92
Est. completion date July 30, 2024
Est. primary completion date July 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - In patients with confirmed HHT diagnosis (= 3 CuraƧao criteria or positive molecular genetics) - aged over 18 years Exclusion Criteria: - if inclusion criteria does not apply

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Tourniquet Test
Tourniquet Test was performed in patients with HHT

Locations

Country Name City State
Germany University Hospital Essen Essen Nordrhein Westphalen

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Essen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of positive Tourniquet Test results in HHT patients Documentation of the number of positive Tourniquet Test results in HHT patients three years
See also
  Status Clinical Trial Phase
Completed NCT06039124 - Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Active, not recruiting NCT04150822 - Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
Recruiting NCT03850964 - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Phase 2/Phase 3
Completed NCT01314274 - Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Phase 2
Completed NCT02389959 - Intranasal Bevacizumab for HHT-Related Epistaxis Phase 4
Active, not recruiting NCT05550376 - Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia